A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
Parkinson Disease
Interventions
DRUG

GRF6021

GRF6021 for IV infusion

OTHER

Placebo

Placebo for IV infusion

Trial Locations (29)

3004

Alfred Hospital, Melbourne

13385

Hopital de la Timone, Marseille

27612

Wake Research, Raleigh

30029

CHU Caremeau, Nîmes

30331

Atlanta Center for Medical Research, Atlanta

30342

NeuroTrials Research Inc., Atlanta

31059

CHU Purpan - Hopital Pierre Paul Riquet, Toulouse

32132

Riverside Clinical Research, Edgewater

33009

MD Clinical, Hallandale

33024

Research Centers of America, LLC, Hollywood

33135

Suncoast Research Group, LLC, Miami

33143

Qps_Mra, Llc, South Miami

33166

Moonshine Research Center, Doral

38043

CHU Grenoble Alpes, Grenoble

44195

Cleveland Clinic, Cleveland

48170

SRI Biosciences, Plymouth

48334

Quest Research Institute, Farmington Hills

59000

Hopital Roger Salengro, Lille

63128

PsychCare Consultants Research, St Louis

69677

Hopital Neurologique, Bron

72205

Clinical Trials, Inc., Little Rock

75390

UT Southwestern Medical Center, Dallas

76000

CHU Charles Nicolle, Rouen

77058

Centex Studies, INC., Houston

80113

Rocky Mountain Movement Disorders Center, Englewood

86021

CHU de Poitiers, Poitiers

94000

Hopital Henri Mondor, Créteil

97239

Oregon Health & Science University, Portland

98007

Northwest Clinical Research Center, Bellevue

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Alkahest, Inc.

INDUSTRY